Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scott Varde Ogilvie Insider Profile
4 Followers
Scott Varde Ogilvie, Director at Seneca Biopharma, holds 86.02K shares in Seneca Biopharma (Ticker: SNCA), holds ― shares in Inspyr Therapeutics (Ticker: NSPX).
Scott Varde Ogilvie has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Scott Varde Ogilvie holds in companies
Most Profitable Insider Trade
The most profitable trade made by Scott Varde Ogilvie
Scott Varde Ogilvie's Trading History
Seneca Biopharma
Jul 06, 2015
Director
Uninformative Buy
―
$51.61K
Inspyr Therapeutics
―
Director
―
―
List of latest transactions for each holding click on a transaction to see Scott Varde Ogilvie's performance on stock
You May Also Like
Scott Varde Ogilvie insider profile FAQ
What is the percentage of profitable transactions made by Scott Varde Ogilvie?
The percentage of profitable transactions made by Scott Varde Ogilvie is ―.
What is the average return per transaction made by Scott Varde Ogilvie?
The average return per transaction made by Scott Varde Ogilvie is ―.
What stocks does Scott Varde Ogilvie hold?
Scott Varde Ogilvie holds: SNCA, NSPX stocks.
What was Scott Varde Ogilvie’s latest transaction?
Scott Varde Ogilvie latest transaction was an Uninformative Buy of ―.
What was Scott Varde Ogilvie's most profitable transaction?
Scott Varde Ogilvie’s most profitable transaction was an Informative Buy of SNCA stock on April 11, 2014. The return on the trade was -51.10%.
What is Scott Varde Ogilvie's role in Seneca Biopharma?
Scott Varde Ogilvie's role in Seneca Biopharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.